Literature DB >> 21897996

C-Reactive protein and outcomes in acute coronary syndromes: a systematic review and meta-analysis.

Luís C L Correia1, J Péricles Esteves.   

Abstract

Despite the association between high-sensitivity C-reactive protein (CRP) and recurrent events in non-ST elevation acute coronary syndromes (ACS), routine determination of this marker has not been recommended. In order to verify whether the current scientific evidence justifies the inclusion of CRP for risk stratification at hospital admission of patients with ACS, we carried out a systematic review and meta-analysis of the studies indexed in MEDLINE, SciELO or LILACS, with the following inclusion criteria: prospective cohort design and assessment of the prognostic value of CPR, as measured using a high-sensitivity method at the moment of hospital admission of patients with ACS. Nineteen studies met the inclusion criteria. In relation to the long-term follow-up, there was a consistent association between CRP and cardiovascular events, with an overall odds ratio (OR) of 4.6 (95% CI = 2.3 - 7.6) and overall multivariate OR of 2.5 (95% CI = 1.8-3.4). As for the short-term, nine studies were positive and six were negative, with an overall OR of 1.65 (95% CI = 1.2-2.3). The overall multivariate OR was not obtained for the short-term follow-up, because this measurement was described only in three heterogeneous studies. Only two short-term studies analyzed the incremental predictive value of CRP in relation to multivariate models, with contradicting results. In conclusion, the small number of assessments of the incremental value of CRP, in conjunction with controversial results regarding the independent predictive value of CRP for short-term events does not support the recommendation of the routine use of CRP for risk stratification at admission of patients with ACS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21897996     DOI: 10.1590/s0066-782x2011005000032

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  7 in total

1.  Risk stratification in acute coronary syndromes.

Authors:  Gabriele Pesarini; Francesco Santini; Giulia Geremia; Carlo Zivelonghi; Flavio Ribichini
Journal:  J Cardiovasc Transl Res       Date:  2011-12-02       Impact factor: 4.132

2.  Maternal plasma soluble TRAIL is decreased in preeclampsia.

Authors:  Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Tamara Stampalija; Nandor Gabor Than; Zhong Dong; Jezid Miranda; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-13

Review 3.  Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations.

Authors: 
Journal:  Arq Bras Cardiol       Date:  2015-05-01       Impact factor: 2.000

4.  Adjustment of the GRACE Risk Score by Monocyte to High-Density Lipoprotein Ratio Improves Prediction of Adverse Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Authors:  Xiaoteng Ma; Kangning Han; Lixia Yang; Qiaoyu Shao; Qiuxuan Li; Zhijian Wang; Yueping Li; Fei Gao; Zhiqiang Yang; Dongmei Shi; Yujie Zhou
Journal:  Front Cardiovasc Med       Date:  2022-01-26

5.  Predictive value of baseline C-reactive protein level in patients with stable coronary artery disease: A meta-analysis.

Authors:  Shuangyan Luo; Jin Zhang; Biyan Li; Hui Wu
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

6.  Does C-reactive protein add prognostic value to GRACE score in acute coronary syndromes?

Authors:  Luis Cláudio Lemos Correia; Isis Vasconcelos; Guilherme Garcia; Felipe Kalil; Felipe Ferreira; André Silva; Ruan Oliveira; Manuela Carvalhal; Caio Freitas; Márcia Maria Noya-Rabelo
Journal:  Arq Bras Cardiol       Date:  2014-05-09       Impact factor: 2.000

Review 7.  Global assessment of C-reactive protein and health-related outcomes: an umbrella review of evidence from observational studies and Mendelian randomization studies.

Authors:  Georgios Markozannes; Charalampia Koutsioumpa; Sofia Cividini; Grace Monori; Konstantinos K Tsilidis; Nikolaos Kretsavos; Evropi Theodoratou; Dipender Gill; John Pa Ioannidis; Ioanna Tzoulaki
Journal:  Eur J Epidemiol       Date:  2020-09-25       Impact factor: 8.082

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.